{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:02:08Z","timestamp":1785139328131,"version":"3.55.0"},"reference-count":341,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P1\u20100208"],"award-info":[{"award-number":["P1\u20100208"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["J1\u201050038"],"award-info":[{"award-number":["J1\u201050038"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Medicinal Research Reviews"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are established Hsp90 clients, making breast cancer models widely used for Hsp90 inhibitor evaluation. However, N\u2010terminal inhibitors are well known to induce a heat shock response (HSR), representing a major limitation in cancer therapy. This has driven the development of alternative modalities, such as C\u2010terminal inhibitors, which in several cases avoid HSR induction. To evaluate Hsp90 inhibitors and characterize their proteomic effects, most studies employ western blotting (WB) as the primary method. On WB, different inhibitors are tested across various concentrations, time points, and breast cancer cell lines for their effects on client, heat shock, and other proteins. This generates extensive data sets that outline the expected WB performance of Hsp90 inhibitors. In this review, we focus on 10 protein families that are commonly used to assess Hsp90 inhibition in in vitro breast cancer models and represent all 10 cancer hallmarks. We provide basic structural and functional information on these families and comprehensively describe the effects of N\u2010 and C\u2010terminal inhibitors on their levels. We summarize WB\u2010based observations for more than 100 Hsp90 inhibitors, outlining the characteristic effects of N\u2010 and C\u2010terminal inhibition, highlighting opportunities for future research, and ending with a suggestion for the WB method design based on best practices observed in literature.<\/jats:p>","DOI":"10.1002\/med.70079","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T07:29:36Z","timestamp":1785137376000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hsp90 Inhibition on the Western Blot: N\u2010Terminal Versus C\u2010Terminal Inhibitors in Breast Cancer"],"prefix":"10.1002","author":[{"given":"Jaka","family":"Dernov\u0161ek","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy University of Ljubljana Ljubljana Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jernej","family":"Cingl","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy University of Ljubljana Ljubljana Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ur\u0161a Pe\u010dar","family":"Fonovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy University of Ljubljana Ljubljana Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5534-209X","authenticated-orcid":false,"given":"Tihomir","family":"Toma\u0161i\u010d","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy University of Ljubljana Ljubljana Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"9","key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3390\/ijms19092560","article-title":"The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease","volume":"19","author":"Hoter A.","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"e_1_2_13_3_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108396","article-title":"Following the Design Path of Isoform\u2010Selective Hsp90 Inhibitors: Small Differences, Great Opportunities","volume":"245","author":"Dernov\u0161ek J.","year":"2023","journal-title":"Pharmacology & Therapeutics"},{"issue":"11","key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41580-023-00640-9","article-title":"Structural and Functional Complexity of HSP90 in Cellular Homeostasis and Disease","volume":"24","author":"Chiosis G.","year":"2023","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"1","key":"e_1_2_13_5_1","doi-asserted-by":"crossref","DOI":"10.1002\/pro.5255","article-title":"Ordered ATP Hydrolysis in the Hsp90 Chaperone Is Regulated by Aha1 and a Conserved Post\u2010Translational Modification","volume":"34","author":"Amoah D. P.","year":"2024","journal-title":"Protein Science"},{"issue":"48","key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"35386","DOI":"10.1074\/jbc.M703844200","article-title":"Dimerization of Hsp90 Is Required for In Vivo Function","volume":"282","author":"Wayne N.","year":"2007","journal-title":"Journal of Biological Chemistry"},{"issue":"48","key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"7120","DOI":"10.1021\/acs.biochem.5b00801","article-title":"Specific Binding of Tetratricopeptide Repeat Proteins to Heat Shock Protein 70 (Hsp70) and Heat Shock Protein 90 (Hsp90) Is Regulated by Affinity and Phosphorylation","volume":"54","author":"Assimon V. A.","year":"2015","journal-title":"Biochemistry"},{"issue":"7893","key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41586-021-04252-1","article-title":"Structure of Hsp90\u2013Hsp70\u2013Hop\u2013GR Reveals the Hsp90 Client\u2010Loading Mechanism","volume":"601","author":"Wang R. Y.\u2010R.","year":"2022","journal-title":"Nature"},{"issue":"6293","key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1126\/science.aaf5023","article-title":"Atomic Structure of Hsp90\u2013Cdc37\u2013Cdk4 Reveals That Hsp90 Traps and Stabilizes an Unfolded Kinase","volume":"352","author":"Verba K. A.","year":"2016","journal-title":"Science"},{"issue":"1","key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s42003-024-05959-3","article-title":"Structural Dynamics of RAF1\u2013HSP90\u2013CDC37 and HSP90 Complexes Reveal Asymmetric Client Interactions and Key Structural Elements","volume":"7","author":"Finci L. I.","year":"2024","journal-title":"Communications Biology"},{"issue":"1","key":"e_1_2_13_11_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/med.21807","article-title":"Targeting the HSP90\u2013CDC37\u2013Kinase Chaperone Cycle: A Promising Therapeutic Strategy for Cancer","volume":"42","author":"Wang L.","year":"2022","journal-title":"Medicinal Research Reviews"},{"issue":"8","key":"e_1_2_13_12_1","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1074\/jbc.M007385200","article-title":"Functional Interaction of Human Cdc37 With the Androgen Receptor but Not With the Glucocorticoid Receptor","volume":"276","author":"Rao J.","year":"2001","journal-title":"Journal of Biological Chemistry"},{"issue":"8","key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2217\/fon.12.80","article-title":"The Double Edge of the HSP90\u2013CDC37 Chaperone Machinery: Opposing Determinants of Kinase Stability and Activity","volume":"8","author":"Xu W.","year":"2012","journal-title":"Future Oncology"},{"issue":"20","key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"10832","DOI":"10.1073\/pnas.170276797","article-title":"Modulation of Akt Kinase Activity by Binding to Hsp90","volume":"97","author":"Sato S.","year":"2000","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"11","key":"e_1_2_13_15_1","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1158\/1535-7163.MCT-13-0284","article-title":"Hsp90 Inhibitors Promote p53\u2010Dependent Apoptosis Through PUMA and Bax","volume":"12","author":"He K.","year":"2013","journal-title":"Molecular Cancer Therapeutics"},{"issue":"10","key":"e_1_2_13_16_1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nsmb.2114","article-title":"Structural Analysis of the Interaction Between Hsp90 and the Tumor Suppressor Protein p53","volume":"18","author":"Hagn F.","year":"2011","journal-title":"Nature Structural & Molecular Biology"},{"issue":"3","key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/iub.607","article-title":"STAT3 Interacts Directly With Hsp90","volume":"64","author":"Prinsloo E.","year":"2012","journal-title":"IUBMB Life"},{"issue":"4","key":"e_1_2_13_18_1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood-2005-07-2648","article-title":"Antiapoptotic Function of Bcl\u20102 in Mast Cells Is Dependent on Its Association With Heat Shock Protein 90\u03b2","volume":"107","author":"Cohen\u2010Saidon C.","year":"2006","journal-title":"Blood"},{"issue":"12","key":"e_1_2_13_19_1","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/onc.2015.213","article-title":"Resistance to HSP90 Inhibition Involving Loss of MCL1 Addiction","volume":"35","author":"Busacca S.","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-cancerbio-030518-055533","article-title":"HSP90: Enabler of Cancer Adaptation","volume":"3","author":"Jaeger A. M.","year":"2019","journal-title":"Annual Review of Cancer Biology"},{"issue":"19","key":"e_1_2_13_21_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910317","article-title":"Role of HSP90 in Cancer","volume":"22","author":"Birbo B.","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"e_1_2_13_22_1","volume-title":"Cancer Statistics","author":"NCI","year":"2015"},{"issue":"3","key":"e_1_2_13_23_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray F.","year":"2024","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"7","key":"e_1_2_13_24_1","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1158\/0008-5472.CAN-06-4511","article-title":"High HSP90 Expression Is Associated With Decreased Survival in Breast Cancer","volume":"67","author":"Pick E.","year":"2007","journal-title":"Cancer Research"},{"issue":"2","key":"e_1_2_13_25_1","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3168","article-title":"Amplification and High\u2010Level Expression of Heat Shock Protein 90 Marks Aggressive Phenotypes of Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer","volume":"14","author":"Cheng Q.","year":"2012","journal-title":"Breast Cancer Research"},{"issue":"4","key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.breast.2012.04.002","article-title":"Breast Cancer and HSP90 Inhibitors: Is There a Role Beyond the HER2\u2010positive Subtype?","volume":"21","author":"De Mattos\u2010Arruda L.","year":"2012","journal-title":"Breast"},{"key":"e_1_2_13_27_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.651516","article-title":"Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2\u2010Positive Breast Cancer Cells","volume":"12","author":"Ye M.","year":"2021","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12943-020-01283-6","article-title":"A Novel HSP90 Inhibitor Targeting the C\u2010Terminal Domain Attenuates Trastuzumab Resistance in HER2\u2010Positive Breast Cancer","volume":"19","author":"Park J. M.","year":"2020","journal-title":"Molecular Cancer"},{"issue":"9","key":"e_1_2_13_29_1","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.3390\/cancers12092630","article-title":"HSP90 Inhibitor, 17\u2010DMAG, Alone and in Combination With Lapatinib Attenuates Acquired Lapatinib\u2010Resistance in ER\u2010Positive, HER2\u2010Overexpressing Breast Cancer Cell Line","volume":"12","author":"Lee H. J.","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cstres.2024.05.005","article-title":"An Update on the Status of HSP90 Inhibitors in Cancer Clinical Trials","volume":"29","author":"Rastogi S.","year":"2024","journal-title":"Cell Stress and Chaperones"},{"issue":"1","key":"e_1_2_13_31_1","first-page":"1","article-title":"HSP90 Inhibitors and Cancer: Prospects for Use in Targeted Therapies","volume":"49","author":"Li Z.\u2010N.","year":"2023","journal-title":"Oncology Reports"},{"issue":"9","key":"e_1_2_13_32_1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2022-1172","article-title":"Pimitespib for the Treatment of Advanced Gastrointestinal Stromal Tumors and Other Tumors","volume":"20","author":"Doi T.","year":"2024","journal-title":"Future Oncology"},{"issue":"1","key":"e_1_2_13_33_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/1535-7163.MCT-14-0219","article-title":"TAS\u2010116, a Highly Selective Inhibitor of Heat Shock Protein 90\u03b1 and \u03b2, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models","volume":"14","author":"Ohkubo S.","year":"2015","journal-title":"Molecular Cancer Therapeutics"},{"key":"e_1_2_13_34_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.129111","article-title":"Recent Advances Toward the Development of Hsp90 C\u2010Terminal Inhibitors","volume":"80","author":"Amatya E.","year":"2023","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"21","key":"e_1_2_13_35_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115080","article-title":"C\u2010Terminal Modulators of Heat Shock Protein of 90 kDa (HSP90): State of Development and Modes of Action","volume":"27","author":"Bickel D.","year":"2019","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"e_1_2_13_36_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107747","article-title":"Assay Design and Development Strategies for Finding Hsp90 Inhibitors and Their Role in Human Diseases","volume":"221","author":"Banerjee M.","year":"2021","journal-title":"Pharmacology & Therapeutics"},{"issue":"20","key":"e_1_2_13_37_1","doi-asserted-by":"crossref","first-page":"8368","DOI":"10.1073\/pnas.0903392106","article-title":"Hsp90 Inhibitor PU\u2010H71, a Multimodal Inhibitor of Malignancy, Induces Complete Responses in Triple\u2010Negative Breast Cancer Models","volume":"106","author":"Caldas\u2010Lopes E.","year":"2009","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"4","key":"e_1_2_13_38_1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3892\/ijmm.2016.2696","article-title":"In Vitro Study Comparing the Efficacy of the Water\u2010Soluble HSP90 Inhibitors, 17\u2010AEPGA and 17\u2010DMAG, With That of the Non\u2011Water\u2010Soluble HSP90 Inhibitor, 17\u2010AAG, in Breast Cancer Cell Lines","volume":"38","author":"Ghadban T.","year":"2016","journal-title":"International Journal of Molecular Medicine"},{"issue":"23","key":"e_1_2_13_39_1","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1038\/s41388-022-02269-y","article-title":"A Novel HSP90 Inhibitor SL\u2010145 Suppresses Metastatic Triple\u2010Negative Breast Cancer Without Triggering the Heat Shock Response","volume":"41","author":"Kim J. Y.","year":"2022","journal-title":"Oncogene"},{"issue":"6","key":"e_1_2_13_40_1","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/cas.70058","article-title":"Pimitespib, an HSP90 Inhibitor, Enhances the Efficacy of PARP Inhibitors in PARP Inhibitor\u2010Insensitive Breast Cancer Cells","volume":"116","author":"Muraoka H.","year":"2025","journal-title":"Cancer Science"},{"issue":"9","key":"e_1_2_13_41_1","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/1878-0261.12686","article-title":"Novel C\u2010Terminal Heat Shock Protein 90 Inhibitors Target Breast Cancer Stem Cells and Block Migration, Self\u2010Renewal, and Epithelial\u2013Mesenchymal Transition","volume":"14","author":"Subramanian C.","year":"2020","journal-title":"Molecular Oncology"},{"issue":"15","key":"e_1_2_13_42_1","doi-asserted-by":"crossref","first-page":"12984","DOI":"10.1021\/acs.jmedchem.4c00932","article-title":"New Class of Hsp90 C\u2010Terminal Domain Inhibitors With Anti\u2010Tumor Properties Against Triple\u2010Negative Breast Cancer","volume":"67","author":"Zajec \u017d.","year":"2024","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"e_1_2_13_43_1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1021\/acs.jmedchem.5b01354","article-title":"Novobiocin Analogues That Inhibit the MAPK Pathway","volume":"59","author":"Hall J. A.","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"issue":"21","key":"e_1_2_13_44_1","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1021\/acs.jmedchem.7b01395","article-title":"Design, Synthesis, and Biological Activities of Vibsanin B Derivatives: A New Class of HSP90 C\u2010Terminal Inhibitors","volume":"60","author":"Shao L.\u2010D.","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"key":"e_1_2_13_45_1","article-title":"Akt: A Double\u2010Edged Sword in Cell Proliferation and Genome Stability","volume":"2012","author":"Xu N.","year":"2012","journal-title":"Journal of Oncology"},{"issue":"6","key":"e_1_2_13_46_1","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1007\/s11030-025-11132-7","article-title":"Structural Insights of AKT and Its Activation Mechanism for Drug Development","volume":"29","author":"Kumar B. H.","year":"2025","journal-title":"Molecular Diversity"},{"issue":"17","key":"e_1_2_13_47_1","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1101\/gad.913901","article-title":"Growth Retardation and Increased Apoptosis in Mice With Homozygous Disruption of the akt1 Gene","volume":"15","author":"Chen W. S.","year":"2001","journal-title":"Genes & Development"},{"issue":"2","key":"e_1_2_13_48_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1172\/JCI16885","article-title":"Severe Diabetes, Age\u2010Dependent Loss of Adipose Tissue, and Mild Growth Deficiency in Mice Lacking Akt2\/PKB\u03b2","volume":"112","author":"Garofalo R. S.","year":"2003","journal-title":"Journal of Clinical Investigation"},{"issue":"6","key":"e_1_2_13_49_1","first-page":"2319","article-title":"The Akt Pathway in Oncology Therapy and Beyond (Review)","volume":"53","author":"Nitulescu G.","year":"2018","journal-title":"International Journal of Oncology"},{"issue":"2","key":"e_1_2_13_50_1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/sj.onc.1205052","article-title":"Delayed Mammary Gland Involution in MMTV\u2013AKT1 Transgenic Mice","volume":"21","author":"Ackler S.","year":"2002","journal-title":"Oncogene"},{"issue":"9","key":"e_1_2_13_51_1","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1158\/0008-5472.CAN-03-3465","article-title":"Activation of Akt\u20101 (PKB\u2010\u03b1) Can Accelerate ErbB\u20102\u2010Mediated Mammary Tumorigenesis but Suppresses Tumor Invasion","volume":"64","author":"Hutchinson J. N.","year":"2004","journal-title":"Cancer Research"},{"issue":"4","key":"e_1_2_13_52_1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cellsig.2008.11.015","article-title":"Function of Akt\/PKB Signaling to Cell Motility, Invasion and the Tumor Stroma in Cancer","volume":"21","author":"Chin Y. R.","year":"2009","journal-title":"Cellular Signalling"},{"issue":"1","key":"e_1_2_13_53_1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12964-019-0450-3","article-title":"Distinct Functions of AKT Isoforms in Breast Cancer: A Comprehensive Review","volume":"17","author":"Hinz N.","year":"2019","journal-title":"Cell Communication and Signaling"},{"issue":"14","key":"e_1_2_13_54_1","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.3390\/cancers13143517","article-title":"Targeting PI3K\/AKT\/mTOR Signaling Pathway in Breast Cancer","volume":"13","author":"Li H.","year":"2021","journal-title":"Cancers"},{"issue":"24","key":"e_1_2_13_55_1","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1038\/sj.onc.1208548","article-title":"Hsp90\u2013Akt Phosphorylates ASK1 and Inhibits ASK1\u2010mediated Apoptosis","volume":"24","author":"Zhang R.","year":"2005","journal-title":"Oncogene"},{"issue":"42","key":"e_1_2_13_56_1","doi-asserted-by":"crossref","first-page":"39858","DOI":"10.1074\/jbc.M206322200","article-title":"Akt Forms an Intracellular Complex With Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function","volume":"277","author":"Basso A. D.","year":"2002","journal-title":"Journal of Biological Chemistry"},{"issue":"12","key":"e_1_2_13_57_1","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.cellsig.2005.03.006","article-title":"Hsp90 Functions to Balance the Phosphorylation State of Akt During C2C12 Myoblast Differentiation","volume":"17","author":"Yun B.\u2010G.","year":"2005","journal-title":"Cellular Signalling"},{"issue":"10","key":"e_1_2_13_58_1","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/sj.bjc.6605066","article-title":"Targeting HSP90 for Cancer Therapy","volume":"100","author":"Mahalingam D.","year":"2009","journal-title":"British Journal of Cancer"},{"issue":"10","key":"e_1_2_13_59_1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the Chaperoning of Cancer","volume":"5","author":"Whitesell L.","year":"2005","journal-title":"Nature Reviews Cancer"},{"issue":"8","key":"e_1_2_13_60_1","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1535-7163.MCT-08-1038","article-title":"Antitumor Efficacy of IPI\u2010504, a Selective Heat Shock Protein 90 Inhibitor Against Human Epidermal Growth Factor Receptor 2\u2013Positive Human Xenograft Models as a Single Agent and in Combination With Trastuzumab or Lapatinib","volume":"8","author":"Leow C. C.","year":"2009","journal-title":"Molecular Cancer Therapeutics"},{"issue":"5","key":"e_1_2_13_61_1","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1158\/1535-7163.MCT-10-0966","article-title":"Antitumor Activity of the Hsp90 Inhibitor IPI\u2010504 in HER2\u2010Positive Trastuzumab\u2010Resistant Breast Cancer","volume":"10","author":"Scaltriti M.","year":"2011","journal-title":"Molecular Cancer Therapeutics"},{"issue":"8","key":"e_1_2_13_62_1","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/sj.onc.1205184","article-title":"Ansamycin Antibiotics Inhibit Akt Activation and Cyclin D Expression in Breast Cancer Cells That Overexpress HER2","volume":"21","author":"Basso A. D.","year":"2002","journal-title":"Oncogene"},{"issue":"2","key":"e_1_2_13_63_1","doi-asserted-by":"crossref","DOI":"10.1186\/bcr1996","article-title":"NVP\u2010AUY922: A Small Molecule HSP90 Inhibitor With Potent Antitumor Activity in Preclinical Breast Cancer Models","volume":"10","author":"Jensen M. R.","year":"2008","journal-title":"Breast Cancer Research"},{"issue":"3","key":"e_1_2_13_64_1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1349-7006.2011.02191.x","article-title":"The Heat Shock Protein 90 Inhibitor, AT13387, Displays a Long Duration of Action In Vitro and In Vivo in Non\u2010Small Cell Lung Cancer","volume":"103","author":"Graham B.","year":"2012","journal-title":"Cancer Science"},{"issue":"2","key":"e_1_2_13_65_1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1158\/1078-0432.CCR-13-2166","article-title":"Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple\u2010Negative Breast Cancer","volume":"20","author":"Proia D. A.","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"e_1_2_13_66_1","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1535-7163.MCT-08-0758","article-title":"BIIB021, an Orally Available, Fully Synthetic Small\u2010Molecule Inhibitor of the Heat Shock Protein Hsp90","volume":"8","author":"Lundgren K.","year":"2009","journal-title":"Molecular Cancer Therapeutics"},{"issue":"12","key":"e_1_2_13_67_1","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1158\/1078-0432.CCR-09-0152","article-title":"CUDC\u2010305, a Novel Synthetic HSP90 Inhibitor With Unique Pharmacologic Properties for Cancer Therapy","volume":"15","author":"Bao R.","year":"2009","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"e_1_2_13_68_1","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1038\/s41598-018-25284-0","article-title":"Ganetespib Targets Multiple Levels of the Receptor Tyrosine Kinase Signaling Cascade and Preferentially Inhibits ErbB2\u2010Overexpressing Breast Cancer Cells","volume":"8","author":"Lee H.","year":"2018","journal-title":"Scientific Reports"},{"issue":"2","key":"e_1_2_13_69_1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bmc.2016.11.030","article-title":"Design, Synthesis and Biological Evaluation of Alkylamino Biphenylamides as Hsp90 C\u2010Terminal Inhibitors","volume":"25","author":"Garg G.","year":"2017","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"9","key":"e_1_2_13_70_1","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1016\/j.bmcl.2010.12.088","article-title":"Identification and Initial SAR of Silybin: An Hsp90 Inhibitor","volume":"21","author":"Zhao H.","year":"2011","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"12","key":"e_1_2_13_71_1","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1021\/jm300544c","article-title":"Synthesis and Evaluation of Novologues as C\u2010Terminal Hsp90 Inhibitors With Cytoprotective Activity Against Sensory Neuron Glucotoxicity","volume":"55","author":"Kusuma B. R.","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"issue":"11","key":"e_1_2_13_72_1","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1021\/jm200148p","article-title":"Engineering an Antibiotic to Fight Cancer: Optimization of the Novobiocin Scaffold to Produce Anti\u2010Proliferative Agents","volume":"54","author":"Zhao H.","year":"2011","journal-title":"Journal of Medicinal Chemistry"},{"key":"e_1_2_13_73_1","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ejmech.2014.10.034","article-title":"Design, Synthesis and Biological Evaluation of Biphenylamide Derivatives as Hsp90 C\u2010Terminal Inhibitors","volume":"89","author":"Zhao H.","year":"2015","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"9","key":"e_1_2_13_74_1","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1039\/C4MD00102H","article-title":"Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C\u2010Terminal Inhibitors","volume":"5","author":"Zhao J.","year":"2014","journal-title":"Medicinal Chemistry Communications"},{"issue":"2","key":"e_1_2_13_75_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1039\/c0md00063a","article-title":"Cytotoxic Sugar Analogues of an Optimized Novobiocin Scaffold","volume":"1","author":"Donnelly A. C.","year":"2010","journal-title":"MedChemComm"},{"issue":"2","key":"e_1_2_13_76_1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bmcl.2012.11.022","article-title":"Novobiocin Analogues With Second\u2010Generation Noviose Surrogates","volume":"23","author":"Zhao H.","year":"2013","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"2","key":"e_1_2_13_77_1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/ml5004475","article-title":"Design, Synthesis, and Biological Evaluation of Ring\u2010Constrained Novobiocin Analogues as Hsp90 C\u2010Terminal Inhibitors","volume":"6","author":"Garg G.","year":"2015","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"1","key":"e_1_2_13_78_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1021\/ml300275g","article-title":"3D\u2010QSAR\u2010Assisted Design, Synthesis, and Evaluation of Novobiocin Analogues","volume":"4","author":"Zhao H.","year":"2013","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"15","key":"e_1_2_13_79_1","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1016\/j.bmcl.2014.05.020","article-title":"Novologues Containing a Benzamide Side Chain Manifest Anti\u2010Proliferative Activity Against Two Breast Cancer Cell Lines","volume":"24","author":"Zhao H.","year":"2014","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"7","key":"e_1_2_13_80_1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1021\/ml100070r","article-title":"Synthesis and Evaluation of Noviose Replacements on Novobiocin That Manifest Antiproliferative Activity","volume":"1","author":"Zhao H.","year":"2010","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"23","key":"e_1_2_13_81_1","doi-asserted-by":"crossref","first-page":"7170","DOI":"10.1016\/j.bmcl.2011.09.073","article-title":"Synthesis and Biological Evaluation of Arylated Novobiocin Analogs as Hsp90 Inhibitors","volume":"21","author":"Kusuma B. R.","year":"2011","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"e_1_2_13_82_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.canlet.2019.01.029","article-title":"C\u2010Terminal HSP90 Inhibitor L80 Elicits Anti\u2010Metastatic Effects in Triple\u2010Negative Breast Cancer via STAT3 Inhibition","volume":"447","author":"Cho T.\u2010M.","year":"2019","journal-title":"Cancer Letters"},{"issue":"7","key":"e_1_2_13_83_1","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.bmc.2019.02.040","article-title":"Investigation of B,C\u2010Ring Truncated Deguelin Derivatives as Heat Shock Protein 90 (HSP90) Inhibitors for Use as Anti\u2010Breast Cancer Agents","volume":"27","author":"Kim H. S.","year":"2019","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"1","key":"e_1_2_13_84_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-020-00384-x","article-title":"Nogo\u2010A Regulates Myogenesis via Interacting With Filamin\u2010C","volume":"7","author":"Park S.","year":"2021","journal-title":"Cell Death Discovery"},{"issue":"8","key":"e_1_2_13_85_1","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/pharmaceutics13081283","article-title":"Structure\u2013Activity Relationships of Benzothiazole\u2010Based Hsp90 C\u2010Terminal\u2010Domain Inhibitors","volume":"13","author":"Dernov\u0161ek J.","year":"2021","journal-title":"Pharmaceutics"},{"key":"e_1_2_13_86_1","first-page":"11","article-title":"Identification and Optimization of Novel 6\u2010Acylamino\u20102\u2010Aminoquinolines as Potent Hsp90 C\u2010Terminal Inhibitors","volume":"14","author":"Jiang F.","year":"2017","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"24","key":"e_1_2_13_87_1","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1002\/cmdc.201700630","article-title":"Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C\u2010Terminal Inhibitors","volume":"12","author":"Byrd K. M.","year":"2017","journal-title":"ChemMedChem"},{"issue":"1","key":"e_1_2_13_88_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/ml400404s","article-title":"Identification of a New Scaffold for Hsp90 C\u2010Terminal Inhibition","volume":"5","author":"Zhao H.","year":"2014","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"4","key":"e_1_2_13_89_1","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.bmc.2013.12.056","article-title":"Synthesis and Biological Evaluation of Coumarin Replacements of Novobiocin as Hsp90 Inhibitors","volume":"22","author":"Kusuma B. R.","year":"2014","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"40","key":"e_1_2_13_90_1","doi-asserted-by":"crossref","first-page":"68329","DOI":"10.18632\/oncotarget.19353","article-title":"Decoding the Full Picture of Raf1 Function Based on Its Interacting Proteins","volume":"8","author":"Huang Y.","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"e_1_2_13_91_1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","article-title":"RAF Protein\u2010Serine\/Threonine Kinases: Structure and Regulation","volume":"399","author":"Roskoski R.","year":"2010","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"5","key":"e_1_2_13_92_1","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.cell.2015.04.045","article-title":"Alike but Different: RAF Paralogs and Their Signaling Outputs","volume":"161","author":"Desideri E.","year":"2015","journal-title":"Cell"},{"issue":"2","key":"e_1_2_13_93_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ccr.2009.06.008","article-title":"Raf\u20101 Addiction in Ras\u2010Induced Skin Carcinogenesis","volume":"16","author":"Ehrenreiter K.","year":"2009","journal-title":"Cancer Cell"},{"issue":"20","key":"e_1_2_13_94_1","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41388-023-02683-w","article-title":"RAF1 Contributes to Cell Proliferation and STAT3 Activation in Colorectal Cancer Independently of Microsatellite and KRAS Status","volume":"42","author":"Dorard C.","year":"2023","journal-title":"Oncogene"},{"issue":"5","key":"e_1_2_13_95_1","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ccr.2011.04.002","article-title":"c\u2010Raf, but Not B\u2010Raf, Is Essential for Development of K\u2010Ras Oncogene\u2010Driven Non\u2010Small Cell Lung Carcinoma","volume":"19","author":"Blasco R. B.","year":"2011","journal-title":"Cancer Cell"},{"issue":"7","key":"e_1_2_13_96_1","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3390\/cancers12071823","article-title":"BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions","volume":"12","author":"Proietti I.","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"e_1_2_13_97_1","doi-asserted-by":"crossref","first-page":"7343","DOI":"10.1038\/s41467-022-35143-2","article-title":"HSP90\u2013CDC37\u2013PP5 Forms a Structural Platform for Kinase Dephosphorylation","volume":"13","author":"Oberoi J.","year":"2022","journal-title":"Nature Communications"},{"issue":"22","key":"e_1_2_13_98_1","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1158\/1078-0432.CCR-18-0565","article-title":"Combined BRAF and HSP90 Inhibition in Patients With Unresectable BRAFV600E\u2010Mutant Melanoma","volume":"24","author":"Eroglu Z.","year":"2018","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"e_1_2_13_99_1","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1158\/1078-0432.CCR-21-3622","article-title":"HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E\u2010Mutant High\u2010Grade Glioma","volume":"28","author":"Sasame J.","year":"2022","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"e_1_2_13_100_1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cell.2012.06.047","article-title":"Quantitative Analysis of Hsp90\u2013Client Interactions Reveals Principles of Substrate Recognition","volume":"150","author":"Taipale M.","year":"2012","journal-title":"Cell"},{"issue":"1","key":"e_1_2_13_101_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1073\/pnas.0609973103","article-title":"V600E B\u2010Raf Requires the Hsp90 Chaperone for Stability and Is Degraded in Response to Hsp90 Inhibitors","volume":"103","author":"Grbovic O. M.","year":"2006","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"41","key":"e_1_2_13_102_1","doi-asserted-by":"crossref","first-page":"24585","DOI":"10.1074\/jbc.270.41.24585","article-title":"Disruption of the Raf\u20101\u2010Hsp90 Molecular Complex Results in Destabilization of Raf\u20101 and Loss of Raf\u20101\u2010Ras Association","volume":"270","author":"Schulte T. W.","year":"1995","journal-title":"Journal of Biological Chemistry"},{"issue":"6","key":"e_1_2_13_103_1","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70489","article-title":"C\u2010Terminal Hsp90 Inhibitors Overcome MEK and BRAF Inhibitor Resistance in Melanoma","volume":"29","author":"Subramanian C.","year":"2025","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"4","key":"e_1_2_13_104_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002800050817","article-title":"The Benzoquinone Ansamycin 17\u2010Allylamino\u201017\u2010Demethoxygeldanamycin Binds to HSP90 and Shares Important Biologic Activities With Geldanamycin","volume":"42","author":"Schulte T. W.","year":"1998","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"13","key":"e_1_2_13_105_1","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1016\/j.bmcl.2010.04.140","article-title":"Click Chemistry to Probe Hsp90: Synthesis and Evaluation of a Series of Triazole Containing Novobiocin Analogues","volume":"20","author":"Peterson L. B.","year":"2010","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"22","key":"e_1_2_13_106_1","doi-asserted-by":"crossref","first-page":"8901","DOI":"10.1021\/jo801312r","article-title":"The Design, Synthesis, and Evaluation of Coumarin Ring Derivatives of the Novobiocin Scaffold That Exhibit Antiproliferative Activity","volume":"73","author":"Donnelly A. C.","year":"2008","journal-title":"Journal of Organic Chemistry"},{"issue":"6","key":"e_1_2_13_107_1","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1021\/jo702191a","article-title":"Development of Novobiocin Analogues That Manifest Anti\u2010Proliferative Activity Against Several Cancer Cell Lines","volume":"73","author":"Burlison J. A.","year":"2008","journal-title":"Journal of Organic Chemistry"},{"issue":"30","key":"e_1_2_13_108_1","doi-asserted-by":"crossref","first-page":"11318","DOI":"10.1073\/pnas.0604705103","article-title":"Hsp90 Inhibition Transiently Activates Src Kinase and Promotes Src\u2010Dependent Akt and Erk Activation","volume":"103","author":"Koga F.","year":"2006","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"12","key":"e_1_2_13_109_1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.molmed.2007.10.002","article-title":"The HER Family and Cancer: Emerging Molecular Mechanisms and Therapeutic Targets","volume":"13","author":"Sergina N. V.","year":"2007","journal-title":"Trends in Molecular Medicine"},{"issue":"4","key":"e_1_2_13_110_1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","article-title":"The Role of HER2, EGFR, and Other Receptor Tyrosine Kinases in Breast Cancer","volume":"35","author":"Hsu J. L.","year":"2016","journal-title":"Cancer and Metastasis Reviews"},{"issue":"7535","key":"e_1_2_13_111_1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nature14067","article-title":"Endophilin Marks and Controls a Clathrin\u2010Independent Endocytic Pathway","volume":"517","author":"Boucrot E.","year":"2015","journal-title":"Nature"},{"issue":"7","key":"e_1_2_13_112_1","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/sj.bjc.6600219","article-title":"Dominant Negative Knockout of p53 Abolishes ErbB2\u2010Dependent Apoptosis and Permits Growth Acceleration in Human Breast Cancer Cells","volume":"86","author":"Huang G. C.","year":"2002","journal-title":"British Journal of Cancer"},{"issue":"42","key":"e_1_2_13_113_1","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1038\/sj.onc.1206779","article-title":"Biologic and Therapeutic Role of HER2 in Cancer","volume":"22","author":"M\u00e9nard S.","year":"2003","journal-title":"Oncogene"},{"issue":"7","key":"e_1_2_13_114_1","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/carcin\/bgm058","article-title":"EGFRvIII Escapes Down\u2010Regulation Due to Impaired Internalization and Sorting to Lysosomes","volume":"28","author":"Grandal M. V.","year":"2007","journal-title":"Carcinogenesis"},{"key":"e_1_2_13_115_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER Family of Protein\u2013Tyrosine Kinases and Cancer","volume":"79","author":"Roskoski R.","year":"2014","journal-title":"Pharmacological Research"},{"issue":"21","key":"e_1_2_13_116_1","doi-asserted-by":"crossref","first-page":"10222","DOI":"10.18632\/oncotarget.2655","article-title":"Regulation of ERBB3\/HER3 Signaling in Cancer","volume":"5","author":"Mujoo K.","year":"2014","journal-title":"Oncotarget"},{"issue":"1","key":"e_1_2_13_117_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging Functions of the EGFR in Cancer","volume":"12","author":"Sigismund S.","year":"2018","journal-title":"Molecular Oncology"},{"issue":"6","key":"e_1_2_13_118_1","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1158\/1078-0432.CCR-13-1549","article-title":"Molecular Pathways: HER3 Targeted Therapy","volume":"20","author":"Gala K.","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"e_1_2_13_119_1","first-page":"355","article-title":"HER3 Signaling and Targeted Therapy in Cancer","volume":"12","author":"Mishra R.","year":"2018","journal-title":"Oncology Reviews"},{"issue":"5","key":"e_1_2_13_120_1","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3892\/etm.2017.4259","article-title":"Role of the PI3K\/AKT Signalling Pathway in Apoptotic Cell Death in the Cerebral Cortex of Streptozotocin\u2010Induced Diabetic Rats","volume":"13","author":"Meng Y.","year":"2017","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"6","key":"e_1_2_13_121_1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S1074-7613(00)80145-4","article-title":"Synergistic Roles for Pim\u20101 and c\u2010Myc in STAT3\u2010mediated Cell Cycle Progression and Antiapoptosis","volume":"11","author":"Shirogane T.","year":"1999","journal-title":"Immunity"},{"issue":"6","key":"e_1_2_13_122_1","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1007\/s11033-020-05435-1","article-title":"Role of PI3K\/AKT Pathway in Cancer: The Framework of Malignant Behavior","volume":"47","author":"Jiang N.","year":"2020","journal-title":"Molecular Biology Reports"},{"issue":"1","key":"e_1_2_13_123_1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK Pathway for Cancer Therapy: From Mechanism to Clinical Studies","volume":"8","author":"Bahar M. E.","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"3","key":"e_1_2_13_124_1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2010.04.009","article-title":"The Role of HER2 in Cancer Therapy and Targeted Drug Delivery","volume":"146","author":"Tai W.","year":"2010","journal-title":"Journal of Controlled Release"},{"issue":"3","key":"e_1_2_13_125_1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/onc.2009.337","article-title":"Inhibitors of HSP90 Block p95\u2013HER2 Signaling in Trastuzumab\u2010Resistant Tumors and Suppress Their Growth","volume":"29","author":"Chandarlapaty S.","year":"2010","journal-title":"Oncogene"},{"key":"e_1_2_13_126_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1006429","article-title":"Trastuzumab Resistance in HER2\u2010Positive Breast Cancer: Mechanisms, Emerging Biomarkers and Targeting Agents","volume":"12","author":"Wang Z.","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"e_1_2_13_127_1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s13046-022-02515-x","article-title":"HER3 in Cancer: From the Bench to the Bedside","volume":"41","author":"Gandullo\u2010S\u00e1nchez L.","year":"2022","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"4","key":"e_1_2_13_128_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0959-8049(01)00230-1","article-title":"The EGFR Family and Its Ligands in Human Cancer","volume":"37","author":"Yarden Y.","year":"2001","journal-title":"European Journal of Cancer"},{"issue":"14","key":"e_1_2_13_129_1","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1158\/0008-5472.CAN-07-5428","article-title":"Hsp90 Inhibition Suppresses Mutant EGFR\u2013T790M Signaling and Overcomes Kinase Inhibitor Resistance","volume":"68","author":"Shimamura T.","year":"2008","journal-title":"Cancer Research"},{"issue":"4","key":"e_1_2_13_130_1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/1535-7163.MCT-12-0507","article-title":"Inhibition of HSP90 With AUY922 Induces Synergy in HER2\u2010Amplified Trastuzumab\u2010Resistant Breast and Gastric Cancer","volume":"12","author":"Wainberg Z. A.","year":"2013","journal-title":"Molecular Cancer Therapeutics"},{"issue":"10","key":"e_1_2_13_131_1","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/ijc.28880","article-title":"HSP90 Inhibitor AUY922 Abrogates Up\u2010Regulation of RTKs by mTOR Inhibitor AZD8055 and Potentiates Its Antiproliferative Activity in Human Breast Cancer","volume":"135","author":"Chen S.\u2010M.","year":"2014","journal-title":"International Journal of Cancer"},{"issue":"1","key":"e_1_2_13_132_1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1158\/1078-0432.CCR-07-1667","article-title":"SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity Against HER Kinase\u2010Dependent Cancers","volume":"14","author":"Chandarlapaty S.","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"e_1_2_13_133_1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1039\/C6MD00377J","article-title":"A Scaffold Merging Approach to Hsp90 C\u2010Terminal Inhibition: Synthesis and Evaluation of a Chimeric Library","volume":"8","author":"Davis R. E.","year":"2017","journal-title":"MedChemComm"},{"issue":"21","key":"e_1_2_13_134_1","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1021\/ol061918j","article-title":"Synthesis and Evaluation of Coumermycin A1 Analogues That Inhibit the Hsp90 Protein Folding Machinery","volume":"8","author":"Burlison J. A.","year":"2006","journal-title":"Organic Letters"},{"issue":"65","key":"e_1_2_13_135_1","doi-asserted-by":"crossref","first-page":"16574","DOI":"10.1002\/chem.201703206","article-title":"Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C\u2010Terminal Inhibitors","volume":"23","author":"Garg G.","year":"2017","journal-title":"Chemistry\u2014A European Journal"},{"issue":"8","key":"e_1_2_13_136_1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1021\/acsmedchemlett.0c00100","article-title":"From Bacteria to Cancer: A Benzothiazole\u2010Based DNA Gyrase B Inhibitor Redesigned for Hsp90 C\u2010Terminal Inhibition","volume":"11","author":"Pugh K. W.","year":"2020","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"18","key":"e_1_2_13_137_1","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1016\/j.bmcl.2017.07.030","article-title":"Modified Biphenyl Hsp90 C\u2010Terminal Inhibitors for the Treatment of Cancer","volume":"27","author":"Forsberg L. K.","year":"2017","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"12","key":"e_1_2_13_138_1","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1016\/j.bmc.2018.04.028","article-title":"Exploiting Polarity and Chirality to Probe the Hsp90 C\u2010Terminus","volume":"26","author":"Forsberg L. K.","year":"2018","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"3","key":"e_1_2_13_139_1","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1039\/D3MD00529A","article-title":"Development of Hsp90 C\u2010Terminal Inhibitors With Noviomimetics That Manifest Anti\u2010Proliferative Activities","volume":"15","author":"Amatya E.","year":"2024","journal-title":"RSC Medicinal Chemistry"},{"issue":"5","key":"e_1_2_13_140_1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/cmdc.201000489","article-title":"Discovery and Biological Activity of 6BrCaQ as an Inhibitor of the Hsp90 Protein Folding Machinery","volume":"6","author":"Audisio D.","year":"2011","journal-title":"ChemMedChem"},{"key":"e_1_2_13_141_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110401","article-title":"\u2018Shedding\u2019 Light on HER4 Signaling in Normal and Malignant Breast Tissues","volume":"97","author":"Brockhoff G.","year":"2022","journal-title":"Cellular Signalling"},{"issue":"6841","key":"e_1_2_13_142_1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/35082500","article-title":"Specific Protection Against Breast Cancers by Cyclin D1 Ablation","volume":"411","author":"Yu Q.","year":"2001","journal-title":"Nature"},{"key":"e_1_2_13_143_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103199","article-title":"The Cyclin\u2010Dependent Kinases Pathway as a Target for Prostate Cancer Treatment: Rationale and Future Perspectives","volume":"157","author":"Brighi N.","year":"2021","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"4","key":"e_1_2_13_144_1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ccr.2012.09.015","article-title":"The Requirement for Cyclin D Function in Tumor Maintenance","volume":"22","author":"Choi Y. J.","year":"2012","journal-title":"Cancer Cell"},{"issue":"24","key":"e_1_2_13_145_1","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1158\/0008-5472.CAN-11-1783","article-title":"Cyclin D3 Compensates for the Loss of Cyclin D1 During ErbB2\u2010Induced Mammary Tumor Initiation and Progression","volume":"71","author":"Zhang Q.","year":"2011","journal-title":"Cancer Research"},{"issue":"12","key":"e_1_2_13_146_1","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.3390\/cells9122648","article-title":"Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma","volume":"9","author":"Montalto F. I.","year":"2020","journal-title":"Cells"},{"issue":"11","key":"e_1_2_13_147_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108151","article-title":"Endogenous Cyclin D1 Promotes the Rate of Onset and Magnitude of Mitogenic Signaling via Akt1 Ser473 Phosphorylation","volume":"32","author":"Chen K.","year":"2020","journal-title":"Cell Reports"},{"issue":"12","key":"e_1_2_13_148_1","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.4161\/cc.3.12.1277","article-title":"Hsp90 Activation and Cell Cycle Regulation","volume":"3","author":"Burrows F.","year":"2004","journal-title":"Cell Cycle"},{"issue":"12","key":"e_1_2_13_149_1","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1101\/gad.10.12.1491","article-title":"Mammalian p50Cdc37 Is a Protein Kinase\u2010Targeting Subunit of Hsp90 That Binds and Stabilizes Cdk4","volume":"10","author":"Stepanova L.","year":"1996","journal-title":"Genes & Development"},{"issue":"13","key":"e_1_2_13_150_1","doi-asserted-by":"crossref","first-page":"12560","DOI":"10.1074\/jbc.M308242200","article-title":"Identification of a Conserved Sequence Motif That Promotes Cdc37 and Cyclin D1 Binding to Cdk4","volume":"279","author":"Zhao Q.","year":"2004","journal-title":"Journal of Biological Chemistry"},{"issue":"5","key":"e_1_2_13_151_1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.celrep.2017.10.042","article-title":"Differential Regulation of G1 CDK Complexes by the Hsp90\u2013Cdc37 Chaperone System","volume":"21","author":"Hallett S. T.","year":"2017","journal-title":"Cell Reports"},{"issue":"5","key":"e_1_2_13_152_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nrm1365","article-title":"RAS and RHO GTPases in G1\u2010phase Cell\u2010Cycle Regulation","volume":"5","author":"Coleman M. L.","year":"2004","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"2","key":"e_1_2_13_153_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056134","article-title":"Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma","volume":"8","author":"Wu X.","year":"2013","journal-title":"PLoS ONE"},{"issue":"1","key":"e_1_2_13_154_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s10637-013-9971-6","article-title":"Targeted Inhibition of Hsp90 by Ganetespib Is Effective Across a Broad Spectrum of Breast Cancer Subtypes","volume":"32","author":"Friedland J. C.","year":"2014","journal-title":"Investigational New Drugs"},{"issue":"8","key":"e_1_2_13_155_1","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein Kinases 6. The Eukaryotic Protein Kinase Superfamily: Kinase (Catalytic) Domain Structure and Classification","volume":"9","author":"Hanks S. K.","year":"1995","journal-title":"FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology"},{"issue":"15","key":"e_1_2_13_156_1","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.3390\/molecules26154462","article-title":"Cyclin\u2010Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment","volume":"26","author":"Susanti N. M. P.","year":"2021","journal-title":"Molecules"},{"issue":"6","key":"e_1_2_13_157_1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in Cancer","volume":"22","author":"Goel S.","year":"2022","journal-title":"Nature Reviews Cancer"},{"issue":"4","key":"e_1_2_13_158_1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ccr.2010.01.023","article-title":"Dissecting the Unique Role of the Retinoblastoma Tumor Suppressor During Cellular Senescence","volume":"17","author":"Chicas A.","year":"2010","journal-title":"Cancer Cell"},{"issue":"1","key":"e_1_2_13_159_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13058-022-01510-6","article-title":"Cellular Mechanisms Underlying Response and Resistance to CDK4\/6 Inhibitors in the Treatment of Hormone Receptor\u2010Positive Breast Cancer","volume":"24","author":"Watt A. C.","year":"2022","journal-title":"Breast Cancer Research"},{"issue":"1","key":"e_1_2_13_160_1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/1878-0261.13541","article-title":"CDK4\/6 Inhibitors Induce Breast Cancer Senescence With Enhanced Anti\u2010Tumor Immunogenic Properties Compared With DNA\u2010Damaging Agents","volume":"18","author":"Lee D. H.","year":"2024","journal-title":"Molecular Oncology"},{"issue":"3","key":"e_1_2_13_161_1","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1021\/acs.jmedchem.0c01700","article-title":"The Development of Hsp90\u03b2\u2010Selective Inhibitors to Overcome Detriments Associated With pan\u2010Hsp90 Inhibition","volume":"64","author":"Mishra S. J.","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"key":"e_1_2_13_162_1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.839005","article-title":"Role of Estrogen Receptors in Health and Disease","volume":"13","author":"Chen P.","year":"2022","journal-title":"Frontiers in Endocrinology"},{"key":"e_1_2_13_163_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","article-title":"Estrogen Receptor Signaling Mechanisms","volume":"116","author":"Fuentes N.","year":"2019","journal-title":"Advances in Protein Chemistry and Structural Biology"},{"issue":"8","key":"e_1_2_13_164_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160312","article-title":"Systematic Proteomic Identification of the Heat Shock Proteins (Hsp) That Interact With Estrogen Receptor Alpha (ER\u03b1) and Biochemical Characterization of the ER\u03b1\u2013Hsp70 Interaction","volume":"11","author":"Dhamad A. E.","year":"2016","journal-title":"PLoS ONE"},{"issue":"21","key":"e_1_2_13_165_1","doi-asserted-by":"crossref","first-page":"16125","DOI":"10.1074\/jbc.M110.104356","article-title":"Differential Requirements of Hsp90 and DNA for the Formation of Estrogen Receptor Homodimers and Heterodimers","volume":"285","author":"Powell E.","year":"2010","journal-title":"Journal of Biological Chemistry"},{"issue":"3","key":"e_1_2_13_166_1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.11613\/BM.2014.035","article-title":"The Many Faces of Estrogen Signaling","volume":"24","author":"Vrta\u010dnik P.","year":"2014","journal-title":"Biochemia Medica"},{"issue":"19","key":"e_1_2_13_167_1","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.3390\/cancers15194689","article-title":"Estrogen Receptor Signaling in Breast Cancer","volume":"15","author":"Miziak P.","year":"2023","journal-title":"Cancers"},{"key":"e_1_2_13_168_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.steroids.2017.11.001","article-title":"Experimental Models for Evaluating Non\u2010Genomic Estrogen Signaling","volume":"133","author":"Stefkovich M. L.","year":"2018","journal-title":"Steroids"},{"key":"e_1_2_13_169_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116941","article-title":"Exploration and Optimisation of Structure\u2013Activity Relationships of New Triazole\u2010Based C\u2010Terminal Hsp90 Inhibitors Towards In Vivo Anticancer Potency","volume":"177","author":"Dernov\u0161ek J.","year":"2024","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"18","key":"e_1_2_13_170_1","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.3390\/ijms21186898","article-title":"Discovery of Novel Hsp90 C\u2010Terminal Inhibitors Using 3D\u2010Pharmacophores Derived From Molecular Dynamics Simulations","volume":"21","author":"Toma\u0161i\u010d T.","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"e_1_2_13_171_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188556","article-title":"Tumor Suppressor p53: Biology, Signaling Pathways, and Therapeutic Targeting","volume":"1876","author":"Hern\u00e1ndez Borrero L. J.","year":"2021","journal-title":"Biochimica et Biophysica Acta (BBA)\u2014Reviews on Cancer"},{"issue":"9","key":"e_1_2_13_172_1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrc3318","article-title":"MicroRNAs in the p53 Network: Micromanagement of Tumour Suppression","volume":"12","author":"Hermeking H.","year":"2012","journal-title":"Nature Reviews Cancer"},{"issue":"1","key":"e_1_2_13_173_1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","article-title":"p53 Signaling in Cancer Progression and Therapy","volume":"21","author":"Marei H. E.","year":"2021","journal-title":"Cancer Cell International"},{"issue":"10","key":"e_1_2_13_174_1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The First 30 Years of p53: Growing Ever More Complex","volume":"9","author":"Levine A. J.","year":"2009","journal-title":"Nature Reviews Cancer"},{"issue":"44","key":"e_1_2_13_175_1","doi-asserted-by":"crossref","first-page":"40583","DOI":"10.1074\/jbc.M102817200","article-title":"Inhibition of MDM2 by hsp90 Contributes to Mutant p53 Stabilization","volume":"276","author":"Peng Y.","year":"2001","journal-title":"Journal of Biological Chemistry"},{"issue":"3","key":"e_1_2_13_176_1","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1128\/MCB.18.3.1517","article-title":"The Physical Association of Multiple Molecular Chaperone Proteins With Mutant p53 Is Altered by Geldanamycin, an hsp90\u2010Binding Agent","volume":"18","author":"Whitesell L.","year":"1998","journal-title":"Molecular and Cellular Biology"},{"issue":"47","key":"e_1_2_13_177_1","doi-asserted-by":"crossref","first-page":"48836","DOI":"10.1074\/jbc.M407601200","article-title":"Hsp90 Chaperones Wild\u2010Type p53 Tumor Suppressor Protein","volume":"279","author":"Walerych D.","year":"2004","journal-title":"Journal of Biological Chemistry"},{"issue":"22","key":"e_1_2_13_178_1","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1093\/emboj\/20.22.6297","article-title":"Co\u2010Chaperones Bag\u20101, Hop and Hsp40 Regulate Hsc70 and Hsp90 Interactions With Wild\u2010Type or Mutant p53","volume":"20","author":"King F. W.","year":"2001","journal-title":"EMBO Journal"},{"issue":"47","key":"e_1_2_13_179_1","doi-asserted-by":"crossref","first-page":"48846","DOI":"10.1074\/jbc.M407687200","article-title":"Hsp90 Regulates the Activity of Wild Type p53 Under Physiological and Elevated Temperatures","volume":"279","author":"M\u00fcller L.","year":"2004","journal-title":"Journal of Biological Chemistry"},{"issue":"48","key":"e_1_2_13_180_1","doi-asserted-by":"crossref","first-page":"15529","DOI":"10.1021\/ja065793p","article-title":"Novobiocin: Redesigning a DNA Gyrase Inhibitor for Selective Inhibition of hsp90","volume":"128","author":"Burlison J. A.","year":"2006","journal-title":"Journal of the American Chemical Society"},{"issue":"3","key":"e_1_2_13_181_1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.bbrc.2013.07.105","article-title":"JAB1 Regulates Unphosphorylated STAT3 DNA\u2010Binding Activity Through Protein\u2013Protein Interaction in Human Colon Cancer Cells","volume":"438","author":"Nishimoto A.","year":"2013","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"43","key":"e_1_2_13_182_1","doi-asserted-by":"crossref","first-page":"31280","DOI":"10.1074\/jbc.M113.505057","article-title":"Mitochondrial Localized Stat3 Promotes Breast Cancer Growth via Phosphorylation of Serine 727","volume":"288","author":"Zhang Q.","year":"2013","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"e_1_2_13_183_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the Complexity of STAT3 in Cancer: Molecular Understanding and Drug Discovery","volume":"43","author":"Hu Y.","year":"2024","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"5","key":"e_1_2_13_184_1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7150\/ijbs.15153","article-title":"Mitochondrial Stat3, the Need for Design Thinking","volume":"12","author":"Yang R.","year":"2016","journal-title":"International Journal of Biological Sciences"},{"issue":"2","key":"e_1_2_13_185_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1530\/ERC-12-0194","article-title":"p42\/p44 MAPK\u2010Mediated Stat3Ser727 Phosphorylation Is Required for Progestin\u2010Induced Full Activation of Stat3 and Breast Cancer Growth","volume":"20","author":"Tkach M.","year":"2013","journal-title":"Endocrine\u2010Related Cancer"},{"issue":"4","key":"e_1_2_13_186_1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/sj.onc.1202382","article-title":"Interleukin\u20106 Dependent Induction of the Cyclin Dependent Kinase Inhibitor p21WAF1\/CIP1 Is Lost During Progression of Human Malignant Melanoma","volume":"18","author":"Fl\u00f8renes V. A.","year":"1999","journal-title":"Oncogene"},{"issue":"3","key":"e_1_2_13_187_1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/abbs\/gmy174","article-title":"E2F Is Required for STAT3\u2010Mediated Upregulation of Cyclin B1 and Cdc2 Expressions and Contributes to G2\u2013M Phase Transition","volume":"51","author":"Sun J.","year":"2019","journal-title":"Acta Biochimica et Biophysica Sinica"},{"issue":"4","key":"e_1_2_13_188_1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0006-291X(02)02941-8","article-title":"Involvement of Heat\u2010Shock Protein 90 in the Interleukin\u20106\u2010Mediated Signaling Pathway Through STAT3","volume":"300","author":"Sato N.","year":"2003","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"e_1_2_13_189_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cellsig.2017.07.014","article-title":"HSP90 Is Necessary for the ACK1\u2010Dependent Phosphorylation of STAT1 and STAT3","volume":"39","author":"Mahendrarajah N.","year":"2017","journal-title":"Cellular Signalling"},{"issue":"2","key":"e_1_2_13_190_1","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.18632\/oncotarget.13579","article-title":"The Non\u2010Receptor Tyrosine Kinase TNK2\/ACK1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer","volume":"8","author":"Wu X.","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"e_1_2_13_191_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-811X-7-17","article-title":"HSP90 Is Essential for Jak\u2010STAT Signaling in Classical Hodgkin Lymphoma Cells","volume":"7","author":"Schoof N.","year":"2009","journal-title":"Cell Communication and Signaling"},{"issue":"1","key":"e_1_2_13_192_1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12885-019-5295-z","article-title":"Overcoming Acquired Resistance to HSP90 Inhibition by Targeting JAK\u2010STAT Signalling in Triple\u2010Negative Breast Cancer","volume":"19","author":"Mumin N. H.","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"e_1_2_13_193_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7150\/thno.63788","article-title":"A Novel C\u2010Terminal Heat Shock Protein 90 Inhibitor That Overcomes STAT3\u2010Wnt\u2010\u03b2\u2010Catenin Signaling\u2010Mediated Drug Resistance and Adverse Effects","volume":"12","author":"Lee H. J.","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"e_1_2_13_194_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL\u20102 Protein Family: Opposing Activities That Mediate Cell Death","volume":"9","author":"Youle R. J.","year":"2008","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"1","key":"e_1_2_13_195_1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/biom10010128","article-title":"The Bcl\u20102 Family: Ancient Origins, Conserved Structures, and Divergent Mechanisms","volume":"10","author":"Banjara S.","year":"2020","journal-title":"Biomolecules"},{"issue":"1","key":"e_1_2_13_196_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/nyas.12045","article-title":"Getting Away With Murder: How Does the BCL\u20102 Family of Proteins Kill With Immunity?","volume":"1285","author":"Renault T. T.","year":"2013","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"20","key":"e_1_2_13_197_1","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1111\/febs.16136","article-title":"Understanding MCL1: From Cellular Function and Regulation to Pharmacological Inhibition","volume":"289","author":"Sancho M.","year":"2022","journal-title":"FEBS Journal"},{"issue":"3","key":"e_1_2_13_198_1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41419-019-1407-6","article-title":"BCL\u20102 Family Isoforms in Apoptosis and Cancer","volume":"10","author":"Warren C. F. A.","year":"2019","journal-title":"Cell Death & Disease"},{"issue":"1","key":"e_1_2_13_199_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12943-022-01516-w","article-title":"BCL\u20102 Expression Promotes Immunosuppression in Chronic Lymphocytic Leukemia by Enhancing Regulatory T Cell Differentiation and Cytotoxic T Cell Exhaustion","volume":"21","author":"Liu L.","year":"2022","journal-title":"Molecular Cancer"},{"issue":"7","key":"e_1_2_13_200_1","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.bbamcr.2013.01.021","article-title":"Non\u2010Apoptotic Roles of Bcl\u20102 Family: The Calcium Connection","volume":"1833","author":"Bonneau B.","year":"2013","journal-title":"Biochimica et Biophysica Acta (BBA)\u2014Molecular Cell Research"},{"issue":"21","key":"e_1_2_13_201_1","doi-asserted-by":"crossref","first-page":"15341","DOI":"10.1074\/jbc.M611594200","article-title":"The Bcl\u20102 Regulator FKBP38\u2010Calmodulin\u2010Ca2+ Is Inhibited by Hsp90","volume":"282","author":"Edlich F.","year":"2007","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_13_202_1","volume-title":"Madame Curie Bioscience Database [Internet]","author":"Bufalo D. Del","year":"2000"},{"issue":"2","key":"e_1_2_13_203_1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1158\/1541-7786.MCR-09-0354","article-title":"Bcl\u20102 Overexpression Induces a Partial Epithelial to Mesenchymal Transition and Promotes Squamous Carcinoma Cell Invasion and Metastasis","volume":"8","author":"Zuo J.","year":"2010","journal-title":"Molecular Cancer Research"},{"issue":"11","key":"e_1_2_13_204_1","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.18632\/oncotarget.1419","article-title":"Mode of Cell Death Induced by the HSP90 Inhibitor 17\u2010AAG (Tanespimycin) Is Dependent on the Expression of Pro\u2010Apoptotic BAX","volume":"4","author":"Powers M. V.","year":"2013","journal-title":"Oncotarget"},{"issue":"4","key":"e_1_2_13_205_1","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1007\/s11033-021-06392-z","article-title":"Debio\u20100932, a Second Generation Oral Hsp90 Inhibitor, Induces Apoptosis in MCF\u20107 and MDA\u2010MB\u2010231 Cell Lines","volume":"48","author":"\u00d6zg\u00fcr A.","year":"2021","journal-title":"Molecular Biology Reports"},{"key":"e_1_2_13_206_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2017.09.040","article-title":"HSP90 Inhibitor (NVP\u2010AUY922) Enhances the Anti\u2010Cancer Effect of BCL\u20102 Inhibitor (ABT\u2010737) in Small Cell Lung Cancer Expressing BCL\u20102","volume":"411","author":"Yang H.","year":"2017","journal-title":"Cancer Letters"},{"issue":"4","key":"e_1_2_13_207_1","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.3892\/etm.2017.4995","article-title":"Effects of 17\u2010DMAG on Diffuse Large B\u2010Cell Lymphoma Cell Apoptosis","volume":"14","author":"Li J.\u2010J.","year":"2017","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"3","key":"e_1_2_13_208_1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1158\/1535-7163.MCT-15-0778","article-title":"Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim Through ER Stress","volume":"15","author":"Wang C. Y.","year":"2016","journal-title":"Molecular Cancer Therapeutics"},{"issue":"12","key":"e_1_2_13_209_1","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/cas.12540","article-title":"Heat Shock Protein 90 Inhibitor NVP\u2010AUY922 Exerts Potent Activity Against Adult T\u2010Cell Leukemia\u2013Lymphoma Cells","volume":"105","author":"Taniguchi H.","year":"2014","journal-title":"Cancer Science"},{"issue":"1","key":"e_1_2_13_210_1","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7894712","article-title":"17\u2010Allylamino\u2010Demethoxygeldanamycin Used Alone or in Combination With Sodium Orthovanadate Promotes Apoptosis and Inhibits Invasion of SH\u2010SY5Y Cells by Modulating PIWIL2","volume":"2020","author":"Tian X.","year":"2020","journal-title":"BioMed Research International"},{"issue":"2","key":"e_1_2_13_211_1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.molonc.2013.12.005","article-title":"Pre\u2010Clinical Efficacy of PU\u2010H71, a Novel HSP90 Inhibitor, Alone and in Combination With Bortezomib in Ewing Sarcoma","volume":"8","author":"Ambati S. R.","year":"2014","journal-title":"Molecular Oncology"},{"issue":"8","key":"e_1_2_13_212_1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12032-023-02107-5","article-title":"The Effects of STA\u20109090 (Ganetespib) and Venetoclax (ABT\u2010199) Combination on Apoptotic Pathways in Human Cervical Cancer Cells","volume":"40","author":"Karademir D.","year":"2023","journal-title":"Medical Oncology"},{"key":"e_1_2_13_213_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.724192","article-title":"Targeting HSP90 Inhibits Proliferation and Induces Apoptosis Through AKT1\/ERK Pathway in Lung Cancer","volume":"12","author":"Niu M.","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"5","key":"e_1_2_13_214_1","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1007\/s00210-023-02807-9","article-title":"Enhancing Therapeutic Efficacy in Breast Cancer: A Study on the Combined Cytotoxic Effects of Doxorubicin and MPC\u20103100","volume":"397","author":"G\u00f6k\u015fen Tosun N.","year":"2024","journal-title":"Naunyn\u2010Schmiedeberg's Archives of Pharmacology"},{"issue":"13","key":"e_1_2_13_215_1","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1158\/0008-5472.CAN-16-3424","article-title":"Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl\u20102 Family Proteins Empower Antitumor Therapeutic Responses","volume":"77","author":"Karpel\u2010Massler G.","year":"2017","journal-title":"Cancer Research"},{"issue":"8","key":"e_1_2_13_216_1","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1271\/bbb.110225","article-title":"SNX\u20102112, a Novel Hsp90 Inhibitor, Induces G2\/M Cell Cycle Arrest and Apoptosis in MCF\u20107 Cells","volume":"75","author":"Wang S.\u2010X.","year":"2011","journal-title":"Bioscience, Biotechnology, and Biochemistry"},{"issue":"6","key":"e_1_2_13_217_1","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.7150\/thno.93236","article-title":"The HSP90 Inhibitor HVH\u20102930 Exhibits Potent Efficacy Against Trastuzumab\u2010Resistant HER2\u2010Positive Breast Cancer","volume":"14","author":"Park M.","year":"2024","journal-title":"Theranostics"},{"issue":"6","key":"e_1_2_13_218_1","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1124\/mol.109.058545","article-title":"KU135, a Novel Novobiocin\u2010Derived C\u2010Terminal Inhibitor of the 90\u2010kDa Heat Shock Protein, Exerts Potent Antiproliferative Effects in Human Leukemic Cells","volume":"76","author":"Shelton S. N.","year":"2009","journal-title":"Molecular Pharmacology"},{"issue":"9","key":"e_1_2_13_219_1","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.3390\/cimb45090443","article-title":"HSP90 Inhibitor PU\u2010H71 in Combination With BH3\u2010Mimetics in the Treatment of Acute Myeloid Leukemia","volume":"45","author":"Seipel K.","year":"2023","journal-title":"Current Issues in Molecular Biology"},{"issue":"2","key":"e_1_2_13_220_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10549-024-07587-1","article-title":"Dual Targeting of HSP90 and BCL\u20102 in Breast Cancer Cells Using Inhibitors BIIB021 and ABT\u2010263","volume":"210","author":"G\u00f6k\u015fen Tosun N.","year":"2025","journal-title":"Breast Cancer Research and Treatment"},{"issue":"2","key":"e_1_2_13_221_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1101\/gad.291518.116","article-title":"PARPs and ADP\u2010Ribosylation: Recent Advances Linking Molecular Functions to Biological Outcomes","volume":"31","author":"Gupte R.","year":"2017","journal-title":"Genes & Development"},{"issue":"18","key":"e_1_2_13_222_1","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1111\/j.1742-4658.2005.04864.x","article-title":"Poly(ADP\u2010Ribose). The Most Elaborate Metabolite of NAD+","volume":"272","author":"B\u00fcrkle A.","year":"2005","journal-title":"FEBS Journal"},{"issue":"8","key":"e_1_2_13_223_1","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/nar\/gkz120","article-title":"Poly(ADP\u2010Ribosyl)Ation by PARP1: Reaction Mechanism and Regulatory Proteins","volume":"47","author":"Alemasova E. E.","year":"2019","journal-title":"Nucleic Acids Research"},{"key":"e_1_2_13_224_1","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.014479","article-title":"The 89\u2010kDa PARP1 Cleavage Fragment Serves as a Cytoplasmic PAR Carrier to Induce AIF\u2010Mediated Apoptosis","volume":"296","author":"Mashimo M.","year":"2021","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_13_225_1","first-page":"171","volume-title":"Cancer Cell Culture: Methods and Protocols","author":"Mullen P.","year":"2004"},{"key":"e_1_2_13_226_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212540","article-title":"Advances in the Use of PARP Inhibitor Therapy for Breast Cancer","volume":"7","author":"McCann K. E.","year":"2018","journal-title":"Drugs in Context"},{"issue":"7","key":"e_1_2_13_227_1","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41416-021-01664-8","article-title":"Combined PARP and HSP90 Inhibition: Preclinical and Phase 1 Evaluation in Patients With Advanced Solid Tumours","volume":"126","author":"Konstantinopoulos P. A.","year":"2022","journal-title":"British Journal of Cancer"},{"issue":"2","key":"e_1_2_13_228_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10549-014-3230-1","article-title":"Biological and Clinical Significance of PARP1 Protein Expression in Breast Cancer","volume":"149","author":"Green A. R.","year":"2015","journal-title":"Breast Cancer Research and Treatment"},{"issue":"6","key":"e_1_2_13_229_1","first-page":"1928","article-title":"17\u2011AAG Synergizes With Belinostat to Exhibit a Negative Effect on the Proliferation and Invasion of MDA\u2011MB\u2011231 Breast Cancer Cells","volume":"43","author":"Zuo Y.","year":"2020","journal-title":"Oncology Reports"},{"key":"e_1_2_13_230_1","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.22850","article-title":"A Model for Handling Cell Stress","volume":"5","author":"Le Breton L.","year":"2016","journal-title":"eLife"},{"issue":"1","key":"e_1_2_13_231_1","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1038\/s41598-018-25404-w","article-title":"HSP90 Inhibitors Disrupt a Transient HSP90\u2010HSF1 Interaction and Identify a Noncanonical Model of HSP90\u2010Mediated HSF1 Regulation","volume":"8","author":"Kijima T.","year":"2018","journal-title":"Scientific Reports"},{"issue":"4","key":"e_1_2_13_232_1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/cells9041046","article-title":"HSF1: Primary Factor in Molecular Chaperone Expression and a Major Contributor to Cancer Morbidity","volume":"9","author":"Prince T. L.","year":"2020","journal-title":"Cells"},{"issue":"2","key":"e_1_2_13_233_1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1242\/jcs.132605","article-title":"HSF1 at a Glance","volume":"127","author":"Vihervaara A.","year":"2014","journal-title":"Journal of Cell Science"},{"issue":"1","key":"e_1_2_13_234_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10549-015-3521-1","article-title":"Heat Shock Factor 1 Induces Cancer Stem Cell Phenotype in Breast Cancer Cell Lines","volume":"153","author":"Wang B.","year":"2015","journal-title":"Breast Cancer Research and Treatment"},{"issue":"45","key":"e_1_2_13_235_1","doi-asserted-by":"crossref","first-page":"18378","DOI":"10.1073\/pnas.1115031108","article-title":"High Levels of Nuclear Heat\u2010Shock Factor 1 (HSF1) Are Associated With Poor Prognosis in Breast Cancer","volume":"108","author":"Santagata S.","year":"2011","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3","key":"e_1_2_13_236_1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cell.2012.06.031","article-title":"HSF1 Drives a Transcriptional Program Distinct From Heat Shock to Support Highly Malignant Human Cancers","volume":"150","author":"Mendillo M. L.","year":"2012","journal-title":"Cell"},{"key":"e_1_2_13_237_1","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.18638","article-title":"Dynamic Control of Hsf1 During Heat Shock by a Chaperone Switch and Phosphorylation","volume":"5","author":"Zheng X.","year":"2016","journal-title":"eLife"},{"issue":"32","key":"e_1_2_13_238_1","doi-asserted-by":"crossref","first-page":"12191","DOI":"10.1074\/jbc.RA119.008822","article-title":"Regulation of the Hsf1\u2010Dependent Transcriptome via Conserved Bipartite Contacts With Hsp70 Promotes Survival in Yeast","volume":"294","author":"Peffer S.","year":"2019","journal-title":"Journal of Biological Chemistry"},{"issue":"14","key":"e_1_2_13_239_1","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019104096","article-title":"Feedback Regulation of Heat Shock Factor 1 (Hsf1) Activity by Hsp70\u2010Mediated Trimer Unzipping and Dissociation From DNA","volume":"39","author":"Kmiecik S. W.","year":"2020","journal-title":"EMBO Journal"},{"issue":"3","key":"e_1_2_13_240_1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.tibs.2021.10.004","article-title":"Molecular Mechanisms of Heat Shock Factor 1 Regulation","volume":"47","author":"Kmiecik S. W.","year":"2022","journal-title":"Trends in Biochemical Sciences"},{"issue":"1","key":"e_1_2_13_241_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112246","article-title":"Hsf1 on a Leash\u2014Controlling the Heat Shock Response by Chaperone Titration","volume":"396","author":"Masser A. E.","year":"2020","journal-title":"Experimental Cell Research"},{"issue":"5","key":"e_1_2_13_242_1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s12192-021-01222-4","article-title":"Gambogic Acid and Gambogenic Acid Induce a Thiol\u2010Dependent Heat Shock Response and Disrupt the Interaction Between HSP90 and HSF1 or HSF2","volume":"26","author":"Pesonen L.","year":"2021","journal-title":"Cell Stress and Chaperones"},{"issue":"4","key":"e_1_2_13_243_1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0092-8674(00)81588-3","article-title":"Repression of Heat Shock Transcription Factor HSF1 Activation by HSP90 (HSP90 Complex) That Forms a Stress\u2010Sensitive Complex With HSF1","volume":"94","author":"Zou J.","year":"1998","journal-title":"Cell"},{"issue":"6","key":"e_1_2_13_244_1","doi-asserted-by":"crossref","first-page":"816","DOI":"10.18632\/oncotarget.991","article-title":"Targeting HSF1 Sensitizes Cancer Cells to HSP90 Inhibition","volume":"4","author":"Chen Y.","year":"2013","journal-title":"Oncotarget"},{"issue":"8","key":"e_1_2_13_245_1","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.3390\/ijms25084209","article-title":"Heat Shock Response and Heat Shock Proteins: Current Understanding and Future Opportunities in Human Diseases","volume":"25","author":"Singh M. K.","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"e_1_2_13_246_1","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3390\/ijms25020876","article-title":"Heat Shock Proteins and Breast Cancer","volume":"25","author":"Zhang M.","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"18","key":"e_1_2_13_247_1","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2174\/1381612828666220513124603","article-title":"The Role of Heat Shock Protein 40 in Carcinogenesis and Biology of Colorectal Cancer","volume":"28","author":"Asgharzadeh F.","year":"2022","journal-title":"Current Pharmaceutical Design"},{"issue":"22","key":"e_1_2_13_248_1","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1007\/s00018-006-6192-6","article-title":"The Diversity of the DnaJ\/Hsp40 Family, the Crucial Partners for Hsp70 Chaperones","volume":"63","author":"Qiu X.\u2010B.","year":"2006","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"2","key":"e_1_2_13_249_1","first-page":"363","article-title":"JDP1 (DNAJC12\/Hsp40) Expression in Breast Cancer and Its Association With Estrogen Receptor Status","volume":"17","author":"De Bessa S.","year":"2006","journal-title":"International Journal of Molecular Medicine"},{"key":"e_1_2_13_250_1","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.2147\/OTT.S253391","article-title":"HNF1A\u2010Induced lncRNA HCG18 Facilitates Gastric Cancer Progression by Upregulating DNAJB12 via miR\u2010152\u20103p","volume":"13","author":"Ma P.","year":"2020","journal-title":"OncoTargets and Therapy"},{"issue":"28","key":"e_1_2_13_251_1","doi-asserted-by":"crossref","first-page":"11792","DOI":"10.1074\/jbc.M117.785113","article-title":"Endoplasmic Reticulum Stress\u2013Induced Degradation of DNAJB12 Stimulates BOK Accumulation and Primes Cancer Cells for Apoptosis","volume":"292","author":"Sopha P.","year":"2017","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"e_1_2_13_252_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12672-023-00645-y","article-title":"DNAJB4 Promotes Triple\u2010Negative Breast Cancer Cell Apoptosis via Activation of the Hippo Signaling Pathway","volume":"14","author":"Fang F.","year":"2023","journal-title":"Discover Oncology"},{"issue":"2","key":"e_1_2_13_253_1","doi-asserted-by":"crossref","DOI":"10.1186\/bcr1874","article-title":"Large Isoform of MRJ (DNAJB6) Reduces Malignant Activity of Breast Cancer","volume":"10","author":"Mitra A.","year":"2008","journal-title":"Breast Cancer Research"},{"issue":"3","key":"e_1_2_13_254_1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12282-019-01042-6","article-title":"Downregulation of DNAJC10 (ERDJ5) Is Associated With Poor Survival in Breast Cancer","volume":"27","author":"Acun T.","year":"2020","journal-title":"Breast Cancer"},{"key":"e_1_2_13_255_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jtherbio.2017.06.004","article-title":"The Small Heat Shock Protein Hsp27: Present Understanding and Future Prospects","volume":"69","author":"Singh M. K.","year":"2017","journal-title":"Journal of Thermal Biology"},{"key":"e_1_2_13_256_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1755-1536-5-7","article-title":"Heat Shock Protein 27 (HSP27): Biomarker of Disease and Therapeutic Target","volume":"5","author":"Vidyasagar A.","year":"2012","journal-title":"Fibrogenesis & Tissue Repair"},{"key":"e_1_2_13_257_1","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.868089","article-title":"Insights Into the Role of Heat Shock Protein 27 in the Development of Neurodegeneration","volume":"15","author":"Holguin B. A.","year":"2022","journal-title":"Frontiers in Molecular Neuroscience"},{"issue":"1","key":"e_1_2_13_258_1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1749-6632.2000.tb05606.x","article-title":"The Interaction of HSP27 With Daxx Identifies a Potential Regulatory Role of HSP27 in Fas\u2010Induced Apoptosis","volume":"926","author":"Charette S. J.","year":"2000","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"30","key":"e_1_2_13_259_1","doi-asserted-by":"crossref","first-page":"27828","DOI":"10.1074\/jbc.M303417200","article-title":"Heat Shock Protein 27 Controls Apoptosis by Regulating Akt Activation","volume":"278","author":"Rane M. J.","year":"2003","journal-title":"Journal of Biological Chemistry"},{"issue":"18","key":"e_1_2_13_260_1","doi-asserted-by":"crossref","first-page":"12305","DOI":"10.1074\/jbc.M801291200","article-title":"Hsp27 Inhibits Bax Activation and Apoptosis via a Phosphatidylinositol 3\u2010Kinase\u2010dependent Mechanism","volume":"283","author":"Havasi A.","year":"2008","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_13_261_1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/1471-2407-8-286","article-title":"Upregulated HSP27 in Human Breast Cancer Cells Reduces Herceptin Susceptibility by Increasing Her2 Protein Stability","volume":"8","author":"Kang S. H.","year":"2008","journal-title":"BMC Cancer"},{"issue":"2","key":"e_1_2_13_262_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2012.06.003","article-title":"Inhibition of HSP70: A Challenging Anti\u2010Cancer Strategy","volume":"325","author":"Goloudina A. R.","year":"2012","journal-title":"Cancer Letters"},{"issue":"11","key":"e_1_2_13_263_1","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.3390\/cells10112996","article-title":"Similarities and Differences of Hsp70, hsc70, Grp78 and Mortalin as Cancer Biomarkers and Drug Targets","volume":"10","author":"Rai R.","year":"2021","journal-title":"Cells"},{"issue":"12","key":"e_1_2_13_264_1","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.3390\/cells10123446","article-title":"HSP70s in Breast Cancer: Promoters of Tumorigenesis and Potential Targets\/Tools for Therapy","volume":"10","author":"Kabakov A. E.","year":"2021","journal-title":"Cells"},{"issue":"12","key":"e_1_2_13_265_1","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.4161\/auto.26448","article-title":"HSPA8\/HSC70 Chaperone Protein: Structure, Function, and Chemical Targeting","volume":"9","author":"Stricher F.","year":"2013","journal-title":"Autophagy"},{"issue":"11","key":"e_1_2_13_266_1","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1021\/acs.jmedchem.0c02091","article-title":"Function, Therapeutic Potential, and Inhibition of Hsp70 Chaperones","volume":"64","author":"Ambrose A. J.","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"e_1_2_13_267_1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3390\/cells9030587","article-title":"HSP70 Multi\u2010Functionality in Cancer","volume":"9","author":"Albakova Z.","year":"2020","journal-title":"Cells"},{"issue":"3","key":"e_1_2_13_268_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101697","article-title":"Two Distinct Classes of Cochaperones Compete for the EEVD Motif in Heat Shock Protein 70 to Tune Its Chaperone Activities","volume":"298","author":"Johnson O. T.","year":"2022","journal-title":"Journal of Biological Chemistry"},{"issue":"2","key":"e_1_2_13_269_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0092-8674(00)80830-2","article-title":"Structure of TPR Domain\u2013Peptide Complexes","volume":"101","author":"Scheufler C.","year":"2000","journal-title":"Cell"},{"issue":"8","key":"e_1_2_13_270_1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrm2941","article-title":"The HSP70 Chaperone Machinery: J Proteins as Drivers of Functional Specificity","volume":"11","author":"Kampinga H. H.","year":"2010","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"11","key":"e_1_2_13_271_1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41580-019-0133-3","article-title":"The Hsp70 Chaperone Network","volume":"20","author":"Rosenzweig R.","year":"2019","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"3","key":"e_1_2_13_272_1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12192-016-0676-6","article-title":"The Human HSP70 Family of Chaperones: Where Do We Stand?","volume":"21","author":"Radons J.","year":"2016","journal-title":"Cell Stress and Chaperones"},{"issue":"2","key":"e_1_2_13_273_1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1128\/MCB.01041-08","article-title":"Heat Shock Protein Hsp72 Controls Oncogene\u2010Induced Senescence Pathways in Cancer Cells","volume":"29","author":"Gabai V. L.","year":"2009","journal-title":"Molecular and Cellular Biology"},{"issue":"17","key":"e_1_2_13_274_1","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/1873-3468.12751","article-title":"Hsp70\u2014A Master Regulator in Protein Degradation","volume":"591","author":"Fern\u00e1ndez\u2010Fern\u00e1ndez M. R.","year":"2017","journal-title":"FEBS Letters"},{"issue":"1","key":"e_1_2_13_275_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41589-019-0415-2","article-title":"Targeting the Interaction of AIMP2\u2010DX2 With HSP70 Suppresses Cancer Development","volume":"16","author":"Lim S.","year":"2020","journal-title":"Nature Chemical Biology"},{"issue":"1","key":"e_1_2_13_276_1","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1038\/s41467-024-48597-3","article-title":"Hsc70 Promotes Anti\u2010Tumor Immunity by Targeting PD\u2010L1 for Lysosomal Degradation","volume":"15","author":"Xu X.","year":"2024","journal-title":"Nature Communications"},{"issue":"13","key":"e_1_2_13_277_1","doi-asserted-by":"crossref","first-page":"10051","DOI":"10.1074\/jbc.M111.335000","article-title":"HSP90 and HSP70 Proteins Are Essential for Stabilization and Activation of WASF3 Metastasis\u2010Promoting Protein","volume":"287","author":"Teng Y.","year":"2012","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"e_1_2_13_278_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/cancers6010042","article-title":"The Complex Function of Hsp70 in Metastatic Cancer","volume":"6","author":"Juhasz K.","year":"2013","journal-title":"Cancers"},{"issue":"1","key":"e_1_2_13_279_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01683-8","article-title":"Alterations of the 70 kDa Heat Shock Protein (HSP70) and sequestosome\u20101 (p62) in Women With Breast Cancer","volume":"11","author":"Orfanelli T.","year":"2021","journal-title":"Scientific Reports"},{"issue":"1","key":"e_1_2_13_280_1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13046-016-0425-9","article-title":"Heat Shock Protein 70\u20102 (HSP70\u20102) Overexpression in Breast Cancer","volume":"35","author":"Jagadish N.","year":"2016","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"1","key":"e_1_2_13_281_1","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1038\/s41598-017-14900-0","article-title":"Cancer Cell Responses to Hsp70 Inhibitor JG\u201098: Comparison With Hsp90 Inhibitors and Finding Synergistic Drug Combinations","volume":"8","author":"Yaglom J. A.","year":"2018","journal-title":"Scientific Reports"},{"issue":"6","key":"e_1_2_13_282_1","first-page":"1501","article-title":"Additive Viability\u2010Loss Following hsp70\/hsc70 Double Interference and Hsp90 Inhibition in Two Breast Cancer Cell Lines","volume":"17","author":"H\u00e5vik B.","year":"2007","journal-title":"Oncology Reports"},{"issue":"3","key":"e_1_2_13_283_1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ccr.2008.08.002","article-title":"Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor\u2010Specific Apoptosis","volume":"14","author":"Powers M. V.","year":"2008","journal-title":"Cancer Cell"},{"issue":"21","key":"e_1_2_13_284_1","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1158\/1078-0432.CCR-11-0821","article-title":"A Phase I Study of PF\u201004929113 (SNX\u20105422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients With Refractory Solid Tumor Malignancies and Lymphomas","volume":"17","author":"Rajan A.","year":"2011","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"e_1_2_13_285_1","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/1541-7786.MCR-15-0234","article-title":"Maximizing the Therapeutic Potential of Hsp90 Inhibitors","volume":"13","author":"Butler L. M.","year":"2015","journal-title":"Molecular Cancer Research"},{"key":"e_1_2_13_286_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1436973","article-title":"HSP90 Multi\u2010Functionality in Cancer","volume":"15","author":"Albakova Z.","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"e_1_2_13_287_1","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cmet.2013.04.019","article-title":"The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase","volume":"17","author":"Sciacovelli M.","year":"2013","journal-title":"Cell Metabolism"},{"issue":"6","key":"e_1_2_13_288_1","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/med.21915","article-title":"The Biology and Inhibition of Glucose\u2010Regulated Protein 94\/gp96","volume":"42","author":"Pugh K. W.","year":"2022","journal-title":"Medicinal Research Reviews"},{"key":"e_1_2_13_289_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2023.102753","article-title":"Interplay Between Calcium and Endoplasmic Reticulum Stress","volume":"113","author":"Groenendyk J.","year":"2023","journal-title":"Cell Calcium"},{"key":"e_1_2_13_290_1","first-page":"7645","article-title":"The Molecular Chaperone TRAP1 in Cancer: From the Basics of Biology to Pharmacological Targeting","author":"Masgras I.","year":"2021","journal-title":"Seminars in Cancer Biology"},{"key":"e_1_2_13_291_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.629846","article-title":"Molecular Chaperone GRP94\/GP96 in Cancers: Oncogenesis and Therapeutic Target","volume":"11","author":"Duan X.","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"47","key":"e_1_2_13_292_1","doi-asserted-by":"crossref","first-page":"19684","DOI":"10.1021\/jacs.1c07099","article-title":"Mitoquinone Inactivates Mitochondrial Chaperone TRAP1 by Blocking the Client Binding Site","volume":"143","author":"Yoon N. G.","year":"2021","journal-title":"Journal of the American Chemical Society"},{"issue":"1","key":"e_1_2_13_293_1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/1471-2407-14-431","article-title":"Combination Treatment With Doxorubicin and Gamitrinib Synergistically Augments Anticancer Activity Through Enhanced Activation of Bim","volume":"14","author":"Park H.\u2010K.","year":"2014","journal-title":"BMC Cancer"},{"issue":"3","key":"e_1_2_13_294_1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ccr.2012.07.015","article-title":"Control of Tumor Bioenergetics and Survival Stress Signaling by Mitochondrial Hsp90s","volume":"22","author":"Chae Y. C.","year":"2012","journal-title":"Cancer Cell"},{"key":"e_1_2_13_295_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2026.119060","article-title":"Inhibition of TRAP1 in the C\u2010Terminal Domain Influences Mitochondria Properties and Breast Cancer Cell Metabolism","volume":"196","author":"Mathieu C.","year":"2026","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"3","key":"e_1_2_13_296_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107531","article-title":"Rational Design of Allosteric and Selective Inhibitors of the Molecular Chaperone TRAP1","volume":"31","author":"Sanchez\u2010Martin C.","year":"2020","journal-title":"Cell Reports"},{"key":"e_1_2_13_297_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114052","article-title":"Synthesis and Antiproliferative Activity of 6BrCaQ\u2010TPP Conjugates for Targeting the Mitochondrial Heat Shock Protein TRAP1","volume":"229","author":"Mathieu C.","year":"2022","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"7","key":"e_1_2_13_298_1","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1021\/acs.jmedchem.6b00085","article-title":"Development of Glucose Regulated Protein 94\u2010Selective Inhibitors Based on the BnIm and Radamide Scaffold","volume":"59","author":"Crowley V. M.","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"issue":"11","key":"e_1_2_13_299_1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nchembio.1335","article-title":"Paralog\u2010Selective Hsp90 Inhibitors Define Tumor\u2010Specific Regulation of Her2","volume":"9","author":"Patel P. D.","year":"2013","journal-title":"Nature Chemical Biology"},{"issue":"19","key":"e_1_2_13_300_1","doi-asserted-by":"crossref","first-page":"10547","DOI":"10.1002\/anie.202015422","article-title":"Selective Inhibition of the Hsp90\u03b1 Isoform","volume":"60","author":"Mishra S. J.","year":"2021","journal-title":"Angewandte Chemie International Edition"},{"issue":"12","key":"e_1_2_13_301_1","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1021\/acsmedchemlett.2c00327","article-title":"Structure\u2013Activity Relationship Study of Tertiary Alcohol Hsp90\u03b1\u2010Selective Inhibitors With Novel Binding Mode","volume":"13","author":"Mishra S. J.","year":"2022","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"e_1_2_13_302_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116934","article-title":"Hiding in Plain Sight: Optimizing Topoisomerase II\u03b1 Inhibitors into Hsp90\u03b2 Selective Binders","volume":"280","author":"Dernov\u0161ek J.","year":"2024","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"1","key":"e_1_2_13_303_1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41467-017-02013-1","article-title":"Structure\u2010Guided Design of an Hsp90\u03b2 N\u2010Terminal Isoform\u2010Selective Inhibitor","volume":"9","author":"Khandelwal A.","year":"2018","journal-title":"Nature Communications"},{"key":"e_1_2_13_304_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117925","article-title":"Optimization of an Hsp90\u03b2\u2010Selective Inhibitor via Exploration of the Hsp90 N\u2010Terminal ATP\u2010Binding Pocket","volume":"297","author":"Serwetnyk M. A.","year":"2025","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"1","key":"e_1_2_13_305_1","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1038\/s41598-025-86647-y","article-title":"Assessment of Hsp90\u03b2\u2010Selective Inhibitor Safety and On\u2010Target Effects","volume":"15","author":"Reynolds T. S.","year":"2025","journal-title":"Scientific Reports"},{"issue":"13","key":"e_1_2_13_306_1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40265-022-01764-6","article-title":"Pimitespib: First Approval","volume":"82","author":"Hoy S. M.","year":"2022","journal-title":"Drugs"},{"key":"e_1_2_13_307_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jare.2023.02.005","article-title":"A Review of Biological Targets and Therapeutic Approaches in the Management of Triple\u2010Negative Breast Cancer","volume":"54","author":"Kumar H.","year":"2023","journal-title":"Journal of Advanced Research"},{"issue":"16","key":"e_1_2_13_308_1","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.7150\/jca.18457","article-title":"Breast Cancer Cell Line Classification and Its Relevance With Breast Tumor Subtyping","volume":"8","author":"Dai X.","year":"2017","journal-title":"Journal of Cancer"},{"issue":"8","key":"e_1_2_13_309_1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ccell.2022.06.010","article-title":"Pan\u2010Cancer Proteomic Map of 949 Human Cell Lines","volume":"40","author":"Gon\u00e7alves E.","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"e_1_2_13_310_1","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1038\/s41467-023-41132-w","article-title":"Systematic Transcriptional Analysis of Human Cell Lines for Gene Expression Landscape and Tumor Representation","volume":"14","author":"Jin H.","year":"2023","journal-title":"Nature Communications"},{"issue":"2","key":"e_1_2_13_311_1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1124\/mol.114.096883","article-title":"Synthesis and Evaluation of a Novel Deguelin Derivative, L80, Which Disrupts ATP Binding to the C\u2010Terminal Domain of Heat Shock Protein 90","volume":"88","author":"Lee S.\u2010C.","year":"2015","journal-title":"Molecular Pharmacology"},{"key":"e_1_2_13_312_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12943-023-01903-x","article-title":"Targeting CRAF Kinase in Anti\u2010Cancer Therapy: Progress and Opportunities","volume":"22","author":"Wang P.","year":"2023","journal-title":"Molecular Cancer"},{"key":"e_1_2_13_313_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116906","article-title":"The Evolution of Small\u2010Molecule Akt Inhibitors From Hit to Clinical Candidate","volume":"279","author":"Tian G.","year":"2024","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"3","key":"e_1_2_13_314_1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bcp.2013.11.014","article-title":"Heat Shock Factor 1 Confers Resistance to Hsp90 Inhibitors Through p62\/SQSTM1 Expression and Promotion of Autophagic Flux","volume":"87","author":"Samarasinghe B.","year":"2014","journal-title":"Biochemical Pharmacology"},{"issue":"23","key":"e_1_2_13_315_1","doi-asserted-by":"crossref","first-page":"10686","DOI":"10.1158\/0008-5472.CAN-05-2632","article-title":"Activated B\u2010RAF Is an Hsp90 Client Protein That Is Targeted by the Anticancer Drug 17\u2010Allylamino\u201017\u2010Demethoxygeldanamycin","volume":"65","author":"Rocha Dias S.","year":"2005","journal-title":"Cancer Research"},{"issue":"12","key":"e_1_2_13_316_1","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1073\/pnas.1016140108","article-title":"Transcriptional and Posttranslational Up\u2010Regulation of HER3 (ErbB3) Compensates for Inhibition of the HER2 Tyrosine Kinase","volume":"108","author":"Garrett J. T.","year":"2011","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"2","key":"e_1_2_13_317_1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1210\/me.2002-0206","article-title":"Estrogen Receptor (ER)\u2010\u03b2 Reduces ER\u03b1\u2010Regulated Gene Transcription, Supporting a \u2018Ying Yang\u2019 Relationship Between ER\u03b1 and ER\u03b2 in Mice","volume":"17","author":"Lindberg M. K.","year":"2003","journal-title":"Molecular Endocrinology"},{"key":"e_1_2_13_318_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114013","article-title":"Discovery of BP3 as an Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of HSP90 for Treating Breast Cancer","volume":"228","author":"Liu Q.","year":"2022","journal-title":"European Journal of Medicinal Chemistry"},{"key":"e_1_2_13_319_1","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2023.1219883","article-title":"Development of the First Geldanamycin\u2010Based HSP90 Degraders","volume":"11","author":"Wurnig S.","year":"2023","journal-title":"Frontiers in Chemistry"},{"key":"e_1_2_13_320_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115690","article-title":"Discovery of X10g as a Selective PROTAC Degrader of Hsp90\u03b1 Protein for Treating Breast Cancer","volume":"260","author":"Jiang Q.","year":"2023","journal-title":"European Journal of Medicinal Chemistry"},{"key":"e_1_2_13_321_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116572","article-title":"Novel Hsp90\u2010Targeting PROTACs: Enhanced Synergy With Cisplatin in Combination Therapy of Cervical Cancer","volume":"275","author":"Liang J.","year":"2024","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"13","key":"e_1_2_13_322_1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1538-7445.AM2021-971","article-title":"Abstract 971: Chaperone\u2010Mediated Protein Degradation (CHAMP): A Novel Technology for Tumor\u2010Targeted Protein Degradation","volume":"81","author":"Foley K. P.","year":"2021","journal-title":"Cancer Research"},{"issue":"1","key":"e_1_2_13_323_1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1021\/acs.jmedchem.2c01648","article-title":"Targeted Protein Degradation Induced by HEMTACs Based on HSP90","volume":"66","author":"Li Z.","year":"2023","journal-title":"Journal of Medicinal Chemistry"},{"issue":"19","key":"e_1_2_13_324_1","doi-asserted-by":"crossref","first-page":"19933","DOI":"10.1021\/acs.jmedchem.5c00409","article-title":"HSP90 Mediates Targeted Degradation of Nonclient Protein PARP1 for Breast Cancer Treatment","volume":"68","author":"Liu W.","year":"2025","journal-title":"Journal of Medicinal Chemistry"},{"issue":"15","key":"e_1_2_13_325_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.3515","article-title":"Pen\u2010866, a Miniature Drug Conjugate of a Heat Shock Protein 90 (HSP90) Ligand Linked to SN38 for Patients With Advanced Solid Malignancies: Phase I and Expansion Cohort Results","volume":"38","author":"Falchook G. S.","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"e_1_2_13_326_1","doi-asserted-by":"crossref","first-page":"16712","DOI":"10.1021\/acs.jmedchem.4c01518","article-title":"Heat Shock Protein 90 Interactome\u2010Mediated Proteolysis Targeting Chimera (HIM\u2010PROTAC) Degrading Glutathione Peroxidase 4 to Trigger Ferroptosis","volume":"67","author":"Dong J.","year":"2024","journal-title":"Journal of Medicinal Chemistry"},{"key":"e_1_2_13_327_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117512","article-title":"Design, Synthesis and Biological Evaluation of WEE1 Degraders via HSP90\u2010mediated Targeting Chimeras for Target Therapy of Acute Myeloid Leukemia","volume":"290","author":"Li X.","year":"2025","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"12","key":"e_1_2_13_328_1","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.molcel.2023.05.021","article-title":"The Hsp90 Molecular Chaperone Governs Client Proteins by Targeting Intrinsically Disordered Regions","volume":"83","author":"Kolhe J. A.","year":"2023","journal-title":"Molecular Cell"},{"issue":"8098","key":"e_1_2_13_329_1","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41586-025-09763-9","article-title":"Inhibitors Supercharge Kinase Turnover Through Native Proteolytic Circuits","volume":"649","author":"Scholes N. S.","year":"2026","journal-title":"Nature"},{"issue":"46","key":"e_1_2_13_330_1","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc3099","article-title":"The Structure\u2013Function Relationship of Oncogenic LMTK3","volume":"6","author":"Ditsiou A.","year":"2020","journal-title":"Science Advances"},{"issue":"2","key":"e_1_2_13_331_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.canlet.2016.08.026","article-title":"Neratinib Induces ErbB2 Ubiquitylation and Endocytic Degradation via HSP90 Dissociation in Breast Cancer Cells","volume":"382","author":"Zhang Y.","year":"2016","journal-title":"Cancer Letters"},{"issue":"8","key":"e_1_2_13_332_1","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/ph18081083","article-title":"Combination Strategies With HSP90 Inhibitors in Cancer Therapy: Mechanisms, Challenges, and Future Perspectives","volume":"18","author":"Kim Y.","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"10","key":"e_1_2_13_333_1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/13543776.2024.2400166","article-title":"An Updated Patent Review of BRD4 Degraders","volume":"34","author":"Ma Z.","year":"2024","journal-title":"Expert Opinion on Therapeutic Patents"},{"issue":"1","key":"e_1_2_13_334_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1042\/BJ20130963","article-title":"The Regulatory Mechanism of a Client Kinase Controlling Its Own Release From Hsp90 Chaperone Machinery Through Phosphorylation","volume":"457","author":"Lu X.","year":"2014","journal-title":"Biochemical Journal"},{"issue":"1","key":"e_1_2_13_335_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22294-x","article-title":"A Critical Path to Producing High Quality, Reproducible Data From Quantitative Western Blot Experiments","volume":"12","author":"Taylor S. C.","year":"2022","journal-title":"Scientific Reports"},{"key":"e_1_2_13_336_1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/978-1-59745-542-8_51","volume-title":"Protein Blotting and Detection: Methods and Protocols","author":"Mathews S. T.","year":"2009"},{"issue":"7","key":"e_1_2_13_337_1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nmeth.2992","article-title":"Single\u2010Cell Western Blotting","volume":"11","author":"Hughes A. J.","year":"2014","journal-title":"Nature Methods"},{"issue":"2","key":"e_1_2_13_338_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/mps6020043","article-title":"Comparison of Automated and Traditional Western Blotting Methods","volume":"6","author":"Sormunen A.","year":"2023","journal-title":"Methods and Protocols"},{"issue":"6","key":"e_1_2_13_339_1","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M111.016675","article-title":"Systematic Identification of the HSP90 Regulated Proteome","volume":"11","author":"Wu Z.","year":"2012","journal-title":"Molecular & Cellular Proteomics"},{"issue":"3","key":"e_1_2_13_340_1","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M111.014654","article-title":"Quantitative Proteomics Reveals That Hsp90 Inhibition Preferentially Targets Kinases and the DNA Damage Response","volume":"11","author":"Sharma K.","year":"2012","journal-title":"Molecular & Cellular Proteomics"},{"issue":"9","key":"e_1_2_13_341_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2025.101043","article-title":"Proteomic Analysis of Hsp90\u03b2\u2010Selective Inhibitors Against Triple\u2010Negative Breast Cancer to Gain a Mechanistic Insight","volume":"24","author":"Reynolds T. S.","year":"2025","journal-title":"Molecular & Cellular Proteomics"},{"issue":"9","key":"e_1_2_13_342_1","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1158\/0008-5472.CAN-15-2186","article-title":"Second\u2010Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells","volume":"76","author":"Ferraldeschi R.","year":"2016","journal-title":"Cancer Research"}],"container-title":["Medicinal Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/med.70079","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/med.70079","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/med.70079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T07:30:16Z","timestamp":1785137416000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/med.70079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":341,"alternative-id":["10.1002\/med.70079"],"URL":"https:\/\/doi.org\/10.1002\/med.70079","archive":["Portico"],"relation":{},"ISSN":["0198-6325","1098-1128"],"issn-type":[{"value":"0198-6325","type":"print"},{"value":"1098-1128","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"2025-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"med.70079"}}